Panacea Biotec Ltd   Report issue

For profit Phase 1 Phase 2
Founded: Munich Germany (1984)
Status: No NME R&D (1984)

Organization Overview

First Clinical Trial
2007
NCT01080560
First Marketed Drug
2012
tacrolimus (prograf)
First NDA Approval
None
Last Known Activity
2017

Timeline

NOW
  • Now

Alternative names

PANACEA | PANACEA BIOTEC LTD

Active Ingredients

Marketed Drugs (3)

prasugrel (effient) (2017)

rizatriptan (maxalt) (2017)

tacrolimus (prograf) (2012)

Drugs in Phase 2 Trials (1)

euphorbia (1 trial)

Drugs in Phase 1 Trials (1)

pbl 1427 (1 trial)

Drugs in Other Trials (3)

cyclosporine (sandimmune) (2 trials)

mycophenolate (CellCept) (2 trials)

tacrolimus (prograf) (4 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Hemorrhoids (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 10
  • # of Trial APIs: 5